Old Mission Investment Co LLC Makes New $1.34 Million Investment in Merck & Co., Inc. $MRK

Key Points

• Old Mission Investment Co. LLC purchased 10,342 Merck shares worth approximately $1.34 million, while institutional investors collectively own 76.07% of the company.
• Merck reported quarterly revenue of $16.61 billion, above estimates of $16.37 billion, and beat adjusted EPS expectations. The company maintained fiscal 2026 EPS guidance of $2.66–$2.76.
• Merck declared a quarterly dividend of $0.85 per share, equivalent to a 2.3% annualized yield. Analysts maintain a “Moderate Buy” consensus with a $148.60 average price target, while insiders sold nearly $30 million of stock during the quarter.

Old Mission Investment Co LLC purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 10,342 shares of the company's stock, valued at approximately $1,338,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MRK. Round Rock Advisors LLC raised its stake in Merck & Co., Inc. by 0.7% in the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company's stock valued at $1,272,000 after purchasing an additional 66 shares in the last quarter. Cascade Financial Partners LLC lifted its position in Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock valued at $1,895,000 after purchasing an additional 80 shares during the last quarter. Somerset Trust Co grew its stake in Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company's stock worth $1,118,000 after buying an additional 81 shares in the last quarter. Stonebridge Financial Group LLC grew its stake in Merck & Co., Inc. by 0.9% in the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock worth $1,124,000 after buying an additional 81 shares in the last quarter. Finally, Stronghold Wealth Management L.L.C. increased its holdings in shares of Merck & Co., Inc. by 2.6% in the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock worth $416,000 after buying an additional 82 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Down 1.3%

Shares of NYSE MRK opened at $150.37 on Friday. The stock has a market capitalization of $370.99 billion, a P/E ratio of 120.30, a PEG ratio of 6.63 and a beta of 0.21. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $156.92. The firm's 50 day simple moving average is $134.64 and its two-hundred day simple moving average is $123.52. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same period in the previous year, the business posted $2.13 EPS. The business's quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP David R. Maraldo sold 18,706 shares of the business's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company's stock, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the sale, the executive vice president owned 110,167 shares of the company's stock, valued at $14,501,282.21. This represents a 9.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Cantor Fitzgerald restated a "neutral" rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an "outperform" rating and a $138.00 target price for the company. Daiwa Securities Group raised Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 target price on the stock in a research note on Wednesday, August 12th. Scotiabank raised their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a "sector outperform" rating in a research report on Tuesday, June 30th. Finally, Weiss Ratings raised Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 25th. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and a consensus target price of $148.60.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source